Table of Content

1. Service Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Lung Cancer Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
5.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
5.2.3. By Region
5.2.4. By Company (2022)
5.3. Market Map
5.3.1. By Cancer Cell Type
5.3.2. By Treatment
6. North America Lung Cancer Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
6.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Lung Cancer Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Cancer Cell Type
6.3.1.2.2. By Treatment
6.3.2. Canada Lung Cancer Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Cancer Cell Type
6.3.2.2.2. By Treatment
6.3.3. Mexico Lung Cancer Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Cancer Cell Type
6.3.3.2.2. By Treatment
7. Europe Lung Cancer Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
7.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Lung Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Cancer Cell Type
7.3.1.2.2. By Treatment
7.3.2. Germany Lung Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Cancer Cell Type
7.3.2.2.2. By Treatment
7.3.3. United Kingdom Lung Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Cancer Cell Type
7.3.3.2.2. By Treatment
7.3.4. Italy Lung Cancer Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Cancer Cell Type
7.3.4.2.2. By Treatment
7.3.5. Spain Lung Cancer Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Cancer Cell Type
7.3.5.2.2. By Treatment
8. Asia-Pacific Lung Cancer Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
8.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Lung Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Cancer Cell Type
8.3.1.2.2. By Treatment
8.3.2. Japan Lung Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Cancer Cell Type
8.3.2.2.2. By Treatment
8.3.3. India Lung Cancer Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Cancer Cell Type
8.3.3.2.2. By Treatment
8.3.4. South Korea Lung Cancer Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Cancer Cell Type
8.3.4.2.2. By Treatment
8.3.5. Australia Lung Cancer Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Cancer Cell Type
8.3.5.2.2. By Treatment
9. South America Lung Cancer Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
9.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Lung Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Cancer Cell Type
9.3.1.2.2. By Treatment
9.3.2. Argentina Lung Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Cancer Cell Type
9.3.2.2.2. By Treatment
9.3.3. Colombia Lung Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Cancer Cell Type
9.3.3.2.2. By Treatment
10. Middle East and Africa Lung Cancer Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
10.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Lung Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Cancer Cell Type
10.3.1.2.2. By Treatment
10.3.2. Saudi Arabia Lung Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Cancer Cell Type
10.3.2.2.2. By Treatment
10.3.3. South Africa Lung Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Cancer Cell Type
10.3.3.2.2. By Treatment
10.3.4. Turkey Lung Cancer Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Cancer Cell Type
10.3.4.2.2. By Treatment
10.3.5. Egypt Lung Cancer Therapeutics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Cancer Cell Type
10.3.5.2.2. By Treatment
11. Market Dynamics
11.1. Drivers
11.1.1. Increasing Prevalence of Lung Cancer.
11.1.2. Rise in the number of Tobacco Smokers
11.1.3. Rise in demand for Immunotherapy
11.2. Challenges
11.2.1. High Cost of Cancer Treatment
11.2.2. Side Effects of Drugs
11.2.3. Lack of skilled workforce
12. Market Trends & Developments
12.1. Product Launches
12.2. Mergers & Acquisitions
12.3. Technological Advancements
13. Clinical Trial Analysis
14. Global Lung Cancer Therapeutics Market: SWOT Analysis
15. Competitive Landscape
15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Financials (In Case of Listed Companies)
15.5. Key Personnel
15.6. SWOT Analysis
15.6.1. AstraZeneca Plc
15.6.2. Boehringer Ingelheim International GmbH.
15.6.3. Bristol-Myers Squibb Company
15.6.4. Eli Lilly and Company
15.6.5. F. Hoffmann-La Roche Ltd.
15.6.6. Merck & Co
15.6.7. Pfizer Inc.
15.6.8. Allergan Inc.
15.6.9. Teva Pharmaceutical Industries Ltd.
15.6.10. Abbvie, Inc.
15.6.11. Johnson & Johnson
15.6.12. Amgen Inc.
15.6.13. Novartis AG
16. Strategic Recommendations